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Abstract. Acute promyelocytic leukemia (APL) is highly curable with the combination of all
retinoic acid (ATRA) and anthracycline based chemotherapy, but the percentage of early deaths 
remains  high.  In  the present  study,  we  report the  clinical,  immunophenotypi
molecular characteristics and outcome of APL patients diagnosed and treated in various Hospitals 
of Greece and Cyprus. 
We describe the data of ninety-five APL patients who were diagnosed during the last 15 years. 
Seven (7.4%) newly diagnosed APL patients died due to intracranial hemorrhage within 72 hours 
of presentation. All but two patients were induced with ATRA alone or ATRA plus chemotherapy. 
The  early  death  rate  was  14.9%.  After  induction  all  80  evaluable  patients  achieved  complete
hematologic remission. The cumulative incidence of relapse was 18.3%. Eight of the ten relapsed 
patients  were  successfully  salvaged,  while  both  patients  with  molecularly  resistant  disease  died 
during salvage treatment. Overall survival (OS) at 5 years was
(DFS) 73.6%. In multivariate analysis of OS age over 60 years, DIC at diagnosis and marginally 
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Acute promyelocytic leukemia (APL) is highly curable with the combination of all
retinoic acid (ATRA) and anthracycline based chemotherapy, but the percentage of early deaths 
remains  high.  In  the present  study,  we  report the  clinical,  immunophenotypi
molecular characteristics and outcome of APL patients diagnosed and treated in various Hospitals 
five APL patients who were diagnosed during the last 15 years. 
nosed APL patients died due to intracranial hemorrhage within 72 hours 
of presentation. All but two patients were induced with ATRA alone or ATRA plus chemotherapy. 
The  early  death  rate  was  14.9%.  After  induction  all  80  evaluable  patients  achieved  complete
hematologic remission. The cumulative incidence of relapse was 18.3%. Eight of the ten relapsed 
patients  were  successfully  salvaged,  while  both  patients  with  molecularly  resistant  disease  died 
during salvage treatment. Overall survival (OS) at 5 years was 78.4% and disease free survival 
(DFS) 73.6%. In multivariate analysis of OS age over 60 years, DIC at diagnosis and marginally 
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Acute promyelocytic leukemia (APL) is highly curable with the combination of all-trans-
retinoic acid (ATRA) and anthracycline based chemotherapy, but the percentage of early deaths 
remains  high.  In  the present  study,  we  report the  clinical,  immunophenotypic,  cytogenetic and 
molecular characteristics and outcome of APL patients diagnosed and treated in various Hospitals 
five APL patients who were diagnosed during the last 15 years. 
nosed APL patients died due to intracranial hemorrhage within 72 hours 
of presentation. All but two patients were induced with ATRA alone or ATRA plus chemotherapy. 
The  early  death  rate  was  14.9%.  After  induction  all  80  evaluable  patients  achieved  complete
hematologic remission. The cumulative incidence of relapse was 18.3%. Eight of the ten relapsed 
patients  were  successfully  salvaged,  while  both  patients  with  molecularly  resistant  disease  died 
78.4% and disease free survival 
(DFS) 73.6%. In multivariate analysis of OS age over 60 years, DIC at diagnosis and marginally Mediterr J Hematol Infect Dis 2011; 3; Open Journal System 
major hemorrhage at presentation were identified as adverse prognostic factors. In the subgroup of 
patients with available data on FLT3 mutation status (49 out of 94), ITD positivity also remained as 
an independent prognostic factor in the final model of OS, together with major hemorrhage and 
marginally high Sanz score. We found a close correlation between the CD2 expression and the 
development of the differentiation syndrome (DS). In conclusion, the main problem in managing 
patients with APL is still the high early death rate.
Introduction. Acute promyelocytic leukemia (APL) is 
a  distinct  subtype  of  acute  myelogenous  leukemia 
(AML)  with  special  biological,  morphological, 
cytogenetic,  and  molecular  characteristics  and  also 
clinical features. Morphologically APL is identified by 
the FAB classification as M3 subtype (hypergranular) 
and its microgranular variant (M3v).
1-5 Cytogenetically 
is  characterized  by  the  t(15;17)(q22;q21)  which  is 
considered to be a favorable cytogenetic aberration.
6-9
In rare cases other translocations as t(11;17), t(5;17)
can be detected.
10 Additional chromosome aberrations 
to t(15;17) have been observed in 23%-43% of APL 
cases without changing the favorable prognosis.
11-15
At the molecular level, the result of the t(15;17) is 
the  formation  of  two  functional  fusion  genes,  PML-
RARα and RARα-PML on the derivative chromosomes 
15 and 17 respectively.
5,8,9,16 A variety of PML-RARα
transcripts [bcr1 or Long (L), bcr3 or Short (S), bcr2 or 
Variable (V)] are produced due to different breakpoints 
in PML gene and alternative splicing in chromosome 
15.
17,18 The FLT3 gene aberrations, including internal 
tandem duplications (ITDs) and D835 (tyrosine kinase 
domain, TKD) mutations occur in 30%-50% in APL. 
However,  the  significance  of  FLT3  mutations  as  a 
prognostic factor is not firmly established.
19-22
With  current  treatment  strategies  with  all-trans-
retinoic  acid  (ATRA)  in  combination  with 
anthracycline  based  chemotherapy,  approximately 
70%-80%  of  patients  with  newly  diagnosed  APL 
carrying PML/RARα achieve long-term remission and 
are probably cured. However, relapses occur in 10%-
30% of patients. The role of cytosine arabinoside and 
other  agents  remains  controversial.  For  patients  in 
whom  chemotherapy  is  contraindicated,  for  elderly 
patients  and  for  some  relapsing  patients  Arsenic 
Trioxide  (ATO)  is  a  suitable  alternative,  as  a  single 
agent  or  in  combination  with  ATRA. There  is  not 
agreement  on  the  most  appropriate  consolidation 
therapy  but  generally  two  to  three  cycles  of 
anthracycline-based  chemotherapy  are  considered 
mandatory. Finally, there is an open debate about the 
need for maintenance treatment.
23-31
Besides the excellent results, serious problems still 
remain: a high early death rate (up to 10% for patients 
who enrolled in clinical trials and higher in real life), 
cardiotoxicity, secondary myelodysplastic  syndromes, 
and  relapse  rising  up  to  20%-30%  in  high  risk 
patients.
30,32,33-37
The APL published data in Greek patients are very 
limited,  usually  restricted  to  case  reports  or  small 
series.
38-41
In the present study, we report on 95 patients from 
Greece  and  Cyprus  in  order  to  clarify  the  clinical, 
cytogenetic  and  molecular  features  as  well  as  their 
outcome. 
Design and methods. Between January 1996 and June 
2011 a total of 95 patients with APL were diagnosed 
and  treated  in  6  tertiary  hospitals  in  Athens,  Patras, 
Nicosia  and  Limassol.  The  diagnosis  was  confirmed 
with cytogenetics for the presence of t(15;17) and/or 
molecular studies for the presence of the PML/RARα
fusion gene. Informed consent was obtained from all 
patients according the Declaration of Helsinki and all 
the  protocols  were  approved  by  the  Research  Ethics 
Committee of the participating hospitals.
Laboratory  monitoring  at  diagnosis  consisted  of 
complete  blood  count,  coagulation  studies,  and 
biochemical  profile.  Bone  marrow  aspirates  were 
collected  for  morphology,  immunophenotyping, 
molecular studies and cytogenetics. A comprehensive 
cardiac assessment was performed. The disease status 
was assessed with morphology and molecular studies 
in  bone  marrow  aspirates in  all  patients  before  each 
cycle of chemotherapy, every three months during the 
first year after the treatment was completed, every four 
months during the second year, and subsequently every 
six months up to five years. In case of a PCR positive 
result  after  the  third  consolidation  course  or  during 
subsequent follow-up a new sample, collected at least 2 
weeks but no more than a month apart, was obtained.
In  case  of  repeated  PCR  positivity  the  patient  was 
defined  as  having  molecular  relapse.
27,28,31 The  Sanz 
risk score was used in  order to  decide the treatment 
intensity  in  some  patients  and  for  analyzing  the 
results.
42
Treatment  protocols:  During  the  first  period  (up  to 
2004) most patients followed the AIDA0493 protocol, 
as  it  has  been  described  previously.
43 In  brief, 
induction:  idarubicin+ATRA,  1
st consolidation: 
idarubicin+cytarabine,  2
nd consolidation: 
mitoxantrone+etoposide,  3
rd consolidation: 
idarubicin+cytarabine+6-thioguanine.  From  2004 
onwards  most  patients  were  treated  according to  the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
PETHEMA  protocols  (LPA1999  and  LPA2005),  as 
they  have  been  described  previously.
35,44,45 In  brief, 
induction:  idarubicin+ATRA,  1
st consolidation: 
idarubicin,  2
nd consolidation:  mitoxantrone,  3
rd
consolidation:  idarubicin.  ATRA  was  added  in  each 
consolidation cycle in the intermediate and high risk 
patients  (protocol  LPA1999).  In  protocol  LPA2005 
ATRA  was  added  in  consolidation  cycles  of  all 
patients, irrespective of their risk group. In addition, 
cytarabine  was  added  in  the  1
st and  the  3
rd cycle  of 
consolidation in the high risk patients. A few patients 
were  treated  according  to  the  European  APL93  and 
APL2000  protocols.
30,46-48 In  brief,  induction: 
ATRA+daunorubicin+cytarabine,  1
st and  2
nd
consolidation:  daunorubicin+cytarabine.  In  most 
patients, regardless the treatment protocol, maintenance 
treatment  with  ATRA+mercaptopourine+methotrexate 
(ATRA+6-MP+MTX) or ATRA alone was given for 
two years.
28,49-51 No CNS prophylaxis was given.
27,52
Supportive  care: When  coagulopathy  was  present 
fresh-frozen  plasma  and  platelet  transfusions  were 
given  with  a  platelet  target  of  30x10
9/L.  Heparin  or 
tranexamic acid was not given. After resolution of the 
coagulopathy fresh-frozen plasma was not  given and 
the platelet transfusions were given when hemorrhagic 
manifestations  and/or  infection  were  present.
27,28
Prophylaxis  for  the  retinoic  acid  syndrome  was  not 
given,  as  the  effectiveness  of  this  procedure  is  not 
established according to previous reports.
47,53-57
The  prophylaxis  during  neutropenia  and  the 
management of neutropenic fever or infection followed 
the protocols of the participating hospitals.  
Immunophenotypic  studies:  Immunophenotypic 
studies  were  performed  on  erythrocyte  lysed  whole 
bone  marrow  samples  with  directly  conjugated 
monoclonal  antibodies.  The  expression  of  HLA-DR, 
CD34, CD15, CD13, CD33, MPO as well as the side 
scatter  (SS)  of  the  abnormal  cell  population  was 
assessed.  Various  lymphoid  markers  (including  CD2 
and  CD56)  were  also  used  in  order  to  assess  their 
aberrant expression.
27,58-61
Cytogenetic  studies:  Chromosome  studies  were 
performed on unstimulated bone marrow cells, cultured 
for 24 and 48 hours at the time of diagnosis, after the 
end  of  treatment  and  when  any  suspicion  for  the 
development  of  myelodysplastic  syndrome  was 
raised.
27 Cytogenetic  analyses  were  performed  on 
trypsin  G-banded  chromosome  preparations  and 
imaging  and  karyotyping  were  performed  via 
microscopy  and  computer  imaging  techniques. 
Karyotypes  were  described  according  to  the 
International  System  for  Human  Cytogenetic 
Nomenclature (ISCN) 2009. Whenever possible at least 
20 metaphases were analyzed in each case. 
Molecular  studies: Conventional  nested  reverse 
transcription PCR (RT-PCR) was used for the detection 
of  the  various  isoforms  of  the  PML-RARα hybrid 
gene.
5,17,27,62 The same method was used for minimal
residual  disease (MRD) monitoring  until  early 2004. 
Subsequently, for a more accurate MRD assessment we 
optimized  the  RQ-PCR  protocols  of  the  three  PML-
RARα isoforms for  use  with the  Lightcycler®/Roche 
and we established a standard approach of fluorescence 
data  acquisition.  MRD  assessment  was  always 
performed in bone marrow samples.
63-68 DNA or RNA 
was  used  in  PCR  or  RT-PCR  respectively  for  the 
detection of the internal tandem duplication (ITD) or 
the point mutation D835 (TKD) of the FLT3 gene.
19,69
Outcome definitions: Complete hematologic remission 
(CHR)  and  relapse  were  defined  according  to  the 
National  Cancer  Institute  criteria.
70,71 Molecular 
remission  was  defined  upon  a  negative  PCR  for  the 
PML-RARα hybrid  gene,  as  described  above.  Early 
death was defined as death occurring during induction 
therapy  or  during  the  aplasia  that  follows  induction. 
Death before treatment  was considered “early death” 
but  was  also  reported  separately.  Molecular  relapse 
was met when there were two positive PCR results for 
the PML-RARα hybrid gene, at least two weeks apart 
each other, in a patient being in molecular remission. 
The  differentiation  syndrome  was  defined  as 
“definitely present” or “probable” according to Frankel 
et al.
27,72,73
Statistical  methods: Nominal  variables  were 
summarized  with  frequencies  and  percentages,  while 
continuous  variables  with  median  value  and  range. 
Comparisons  between  groups  were  done  using  the 
Mann-Whitney  or  Kruskal-Wallis  test  for  continuous 
variables, and Pearson’s chi square or Fisher’s exact 
test for categorical data. 
OS was calculated from the first day of induction 
treatment, while DFS was calculated from the date of 
complete  hematologic  response.  Molecular  and/or 
hematologic relapse, PML/RARα PCR positivity at the 
end of consolidation treatment, diagnosis of MDS and 
death irrespective of cause were defined as DFS events. 
OS  and  DFS  were  estimated  by  the  Kaplan-Meier 
method.
Response and  relapse  cumulative  incidences  were 
calculated  considering  death  as  competing  risk. 
Cumulative incidence of relapse (CIR) was calculated 
from  the  date  of  complete  hematologic  remission. 
Molecular or hematologic relapse and PCR positivity at 
the end of consolidation were defined as relapse events.
Effects on survival outcomes were tested by the log-
rank test (OS and DFS) and Cox proportional hazards 
model. Cause specific hazard analysis was done in the 
presence  of  competing  risks.  Significant  (p≤0.1) 
predictors from univariate analysis were further tested 
in multivariate models. The final model in multivariate Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Baseline characteristics of patients.
Characteristic Value
n 95
Median age, y (range) 48 (14-86)
Male, n (%) 39 (41)
APL morphology
       hypergranular n (%)
       microgranular n (%)
77 (83)
16 (17)
De novo, n (%)
Therapy related, n (%)
86 (91)
9 (9)
WBC (x10
9/L), median (range) 1.6 (0.3-106.6)
Platelets (x10
9/L), median (range) 23 (1-275)
Risk category*, n (%)
      low 
      intermediate 
      high 
24 (25)
48 (51)
23 (24)
*According to Sanz et al.
analysis was reached by stepwise backward selection. 
Logistic  regression  was  employed  for  analysis  of 
early death rate and differentiation syndrome risk. 
All  analyses  were  performed  with  STATA  11 
software (StataCorp. 2009. Stata Statistical Software: 
Release 11. College Station, TX: StataCorp LP).
Results. Demographic  and baseline characteristics  of 
the patients are shown in Table 1. 
In nine patients the disease was therapy related (t-
APL). Six patients had been treated with chemotherapy 
or irradiation because of some malignant disorder. In 
addition,  there  were  three  patients  with  multiple 
sclerosis  that  had  been  treated  with  mitoxantrone. 
Details for these patients are shown in Table 2.
74-78
Immunophenotyping: Most patients studied showed an 
“abnormal” cell population with intermediate to high 
side scatter in the CD45/SS dot plot. All patients but 
one (59/60, 98.3%) showed the characteristic absence 
to low percentage of HLA-DR. Actually this particular 
patient showed the variant translocation t(11;17). Only 
3/58 (5.2%) were CD34 positive. CD15 positivity was 
not so rare, to be found in 12/62 patients (19.3%). The 
sharp strong expression of CD33 was a constant feature 
in  all  patients  and  it  was  accompanied  by  variable 
CD13  expression.  MPO,  where  studied,  was  found 
positive in all patients. CD11b was found positive in a 
low  percentage  of  patients  (3/43,  7.0%)  and  CD117 
expression  was  variable.  Aberrant  expression  of 
lymphoid markers was found in 8/49 (16.3%) patients. 
CD2 expression was the more frequent finding (7/44, 
15.9%), whereas CD7 was found in only one patient 
(1/60, 1.7%) and CD56 in two patients (2/49, 4.1%). 
Aberrant  expression  of  lymphoid  markers  was  not 
associated with bad prognosis (OS and DFS); as we 
observed  only  one  molecular  relapse  event  and  no 
deaths among these eight patients. There was a close 
correlation  between  the  expression  of  lymphoid 
markers  and  the  development  of  the  differentiation 
syndrome:  7/8  cases  expressing  lymphoid  markers 
developed DS. No other correlation was found between 
immunophenotype and other features or outcomes of 
the patients, but it has to be stressed that the numbers 
were rather small.
58-61,79
Table 2. Therapy related APL. Characteristics of patients.
Gender Age, 
y
Primary 
disease Treatment
Years 
between 
treatment 
and APL
Morphology Risk 
category* Cytogenetics
PML-
RARα 
isoform
FLT3 
muta-
tions
M 65 Bladder 
carcinoma Surgical, RT 11 Hypergranular Intermediate ND bcr3 wt
M 25 Hodgkin 
Lymphoma Chemo 4 Hypergranular Low 46XY bcr1 wt
M 75 Hepatoma Chemo 3 Hypergranular High ND bcr3 TKD
F 79 Soft tissue  
sarcoma
Surgical, 
Chemo, RT 2 Microgranular Intermediate 46,XX,t(15;17)(q22;q21) bcr1 ND
F 36 Cervical 
carcinoma Surgical, RT 1 Microgranular Intermediate 46,XX,t(15;17)(q22;q21) ND ND
F 67 Breast 
cancer Chemo 2 Hypergranular High NA bcr3 ND
M 50 Multiple 
Sclerosis Mitoxantrone 22 Hypergranular High 46,XY,t(15;17)(q22;q21) bcr1 wt
F 45 Multiple 
Sclerosis Mitoxantrone 2 Hypergranular Intermediate 46XX,add(12q),-
17,+mar bcr1 wt
F 45 Multiple 
Sclerosis
INF, 
Mitoxantrone 13 Hypergranular Intermediate 46ΧΧ,inv(9)(p11q13), 
t(15;17)(q22;q21) NA ND
RT: Radiotherapy, ND: not done, NA: not available. *according to Sanz et al.Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Abnormal karyotypes (in 59 from 68 cases studied).
Groups of abnormal Karyotypes ACA to t(15;17) or CA without  t(15;17) Number of 
patients
t(15;17)(q22;q21) sole 37
t(15;17)(q22;q21) with ACA* 15
+8 (sole)/total 3 /7
del(9q) 1
t(15;17)(q11;q11) 1
der(17)t(15;17)(q22;q21) 1
+21,+add(8p) 1
-Y,+10 1
+8,+mar 1
t(8;21),+8,-10 1
del(Xp),-20,add(21q),+mar 1
der(15)del(15q)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21) 1
+8,der(15)t(15;17)(q22;q21),ider(17)(q10),t(15;17)(q22;q21) 1
t(1;15;17)(q21;q22;q12), der(7) 1
t(15;18;17)(q22;q21;q21) 1
Variant translocation without the involvement of 
chromosome 15 t(11;17),-10,der(?) 1
Chromosomal abnormalities without  t(15;17) or its 
variants 6
8 3
add(16q) 1
add(12q),-17,+mar 1
-15,+19,+mar1,+mar2 1
Abnormal karyotypes categorized into four groups. ACA: additional chromosomal abnormalities, CA: chromosomal abnormalities. *Patients 
with der(17)t(15;17), der(15)t(15;17), ider(17q) or three way translocations including chromosomes 15 and 17 were placed in the group of 
ACAs. 
Chromosomal  abnormalities: Comprehensive 
karyotypic  results  were available in  68 patients. The
detailed  karyotypic  results  are  shown  in  Table  3.
Normal karyotype was found in 9 patients (13.2%).
Among the 59 cases with abnormal karyotype there 
were 42 cases with a single abnormality, seven cases 
with  two  abnormalities,  and  10  cases  with  3 
abnormalities (complex karyotype). The t(15;17) was 
found  in  52  cases  (76.5%)  and  it  was  the  sole 
abnormality in 37 cases. In 15 cases (28.8%) additional 
chromosomal  abnormalities  (ACAs)  were  present. 
Among  the  ACAs  trisomy  8  was  by  far  the  most 
frequent;
12-15 it was present in 7/15 cases. One patient 
showed t(8;21) in addition to t(15;17). He was treated 
with a hybrid protocol (AIDA and a conventional AML 
protocol)  but  he  never  achieved  molecular  CR.
80,81
There was not any difference between the patients with
ACAs and those without ACAs concerning the clinical 
features  (data  not  shown)  or  the  response  to 
treatment.
11,15
Molecular findings: The presence of PML-RARα was 
tested  in  all  but  two  patients and  it  was  detected  in 
92/93  cases  (98.9%).  It  was  absent  in  the  case  with 
t(11;17), as expected. In 75 patients the PML-RARα
isoforms were determined: L isoform (bcr1) in 38 cases 
(51%), V isoform (bcr2) in 5 cases (7%), and S isoform 
(bcr3)  in  32  cases  (42%).
5,17,18 There  was  a  striking 
difference in the frequency of the isoforms between the 
patients  from Greece  and  those  from Cyprus.  In the 
Greek  origin  patients  the  L  isoform  was  present  in 
36/64  cases  (56.25%)  and  the  S  isoform  in  24/64 
(37.5%) while the corresponding figures for the Cyprus 
origin  patients  was  2/11  (18.2%)  and  8/11  (72.7%) 
(p=0.036). 
Fifty one bone marrow samples were analyzed for 
FLT3 mutations at presentation. Mutations were found 
in  20  cases  (39%):  ITD  in  11  cases  and  TKD  in  9 
cases.
19,20,82 The  presence  of  FLT3  mutations  was 
significantly  associated  with  intermediate/high  risk 
score  (p=0.035).
82 The  microgranular  variant  was 
rather more frequent in FLT3 mutated cases (p=0.09).
Coagulopathy was significantly more prevalent among 
FLT3  mutated  cases  (p=0.037).  FLT3  ITD  was  an 
adverse  prognostic  factor  for  early  death  and  OS Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
(p=0.017)  but  not  for  response  rate or  relapse 
incidence.
19,20,82 In one patient we observed a constant 
positivity for FLT3 TKD for 4 years while he remained
in molecular remission.
19,21
Clinical course: At presentation laboratory findings of 
disseminated intravascular coagulation were present in 
54/95 patients (57%). In 26 cases major hemorrhagic 
events  were  noticed.  There  were  9  patients  with 
intracranial bleeding. Hemorrhage was the main cause 
of death in 9 patients: 3 within the first 24 hours, 3 at 
day two, and the others at day 8, 10, and 14. Two of 
these patients died before specific treatment was given. 
Twenty six patients presented with infection.
46,47,83
Induction therapy: Induction treatment was given in 
88  patients:  AIDA  protocol  (n=69),
43 ATRA  alone 
(n=4),
84-86 ATRA+idarubicin+cytarabine (n=13).
30 Two 
patients misdiagnosed as AML-M2 were treated with 
“3+7”.
87 When  the  diagnosis  was  confirmed  they 
followed the AIDA protocol. One patient discontinued 
treatment  because  cytogenetics  showed  t(11;17)  and 
her  age in  conjunction with  poor performance  status 
prohibited further treatment.
88,89 She died a few weeks 
later. She was excluded from further analysis. Twenty 
seven  patients  (31%)  developed  differentiation 
syndrome.
73 In 5 cases (6%) this was definite. In all the 
patients  developing  DS,  dexamethasone  and 
furosemide were administered. ATRA was temporarily 
discontinued  in  9  cases  and  its  dose  reduced  in  one 
case. In 3 cases the DS was the main or a contributory 
cause of death during induction. In all the other cases it 
resolved  within  a  few  days.
27,72 In  4  patients  (5%) 
pseudotumor cerebri developed. All these patients were 
female and their age was 19 (n=2), 22 and 67 years old. 
Temporal discontinuation or dose reduction of ATRA 
in  conjunction  with  dexamethasone  and  diuretic 
administration  was  followed  by  resolution  of  the 
symptoms.
27,43 Infection experienced 62 patients during 
induction  with  neutropenic  fever  being  the  most 
common manifestation (n=42). In one case, pneumonia 
was  the  direct  cause  of  death  and  in  two  cases  a 
contributing  cause.  Eight  patients  died  during 
induction. Median time to death was 14 days (range, 8-
55).  All  but  one  of  those  patients  died  before being 
evaluated for response. The patient that died on day 55 
was in CHR. Causes of death: intracranial hemorrhage 
(n=3), pneumonia and differentiation syndrome (n=2), 
pneumonia (n=1)  septic shock (n=1), and respiratory 
failure because of differentiation syndrome (n=1). All 
80 patients that completed induction and survived the 
early  period  achieved  CHR  at  a  median  of  35  days 
(range,  19-99).  These  patients  were  candidates  for 
consolidation. 
Consolidation  therapy: From  the  80  patients  that 
achieved  complete  hematologic  remission  after 
induction, 76 proceeded to consolidation. One patient 
died  because  of  lung  infection  while  in  CHR.  One 
patient 84 years old was induced with ATRA alone and 
achieved molecular remission.
84-86 Because of her poor 
performance  status  she  was  offered  no  further 
treatment. She had a molecular relapse after 39 months 
and a hematologic relapse after 30 further months. She 
then  received  AIDA  induction 
43 but  she  died  in 
aplasia. The other two patients decided by themselves 
to discontinue further treatment. The first consolidation 
cycle varied according to the protocol that the patient 
followed:  AIDA  (n=39),
43 PETHEMA  (n=24),
35,44,45
European  APL  (n=7),
30,46-48 other  (n=6).  There  were 
two  deaths  because  of  infection  and  one  patient 
experienced  severe  organ  toxicity  after  the 1
st
consolidation cycle and, therefore, 73 patients received 
the 2
nd consolidation cycle. The patients followed the 
same  protocols.  One  patient  died  after  the  2
nd
consolidation  because  of  infection,  one  developed 
severe  organ  toxicity,  one  relapsed,  one  developed 
myelodysplasia and two were considered unfit for any 
further  chemotherapy.  Two  other  patients  were 
scheduled  to  receive  the  3
rd consolidation  when  the 
charts were reviewed. Therefore the 3
rd consolidation 
cycle  was  given to  65  patients. No  deaths or severe 
toxicity was noticed after the 3
rd consolidation cycle. 
Maintenance: A  total  of  64  patients  received 
maintenance at a median time of 187 days (range, 89-
303)  from  the  start  of  the  induction  therapy.
24,28,49-51
Thirty five patients received ATRA alone (median, 8 
cycles),  28  received  ATRA+MTX+6-MP  (median,  8 
cycles)  and  one  patient  received  only  MTX+6-MP 
because her pseudotumor cerebri symptoms reappeared 
when  ATRA  was  given.  No  other  grade  3 
hematologic or non-hematologic toxicity was noticed 
during  maintenance.  Fifteen  patients  are  still  on 
maintenance. Four  patients discontinued  maintenance 
because of relapse.
Outcomes.  Early  death:  The  early  death  rate  was 
14.9%.  (Table  4)  Significant  predictors  of  increased 
risk of early death  on univariate analysis were older 
age,  leykocytosis,  thrombocytopenia,  higher  Sanz 
score, DIC, major hemorrhage, infection at diagnosis 
and FLT3 ITD mutation (Table 5). No association of 
early death with morphologic subtype, secondary APL, 
transcript breakpoint, FLT3 TKD, karyotypic group or 
gender  could  be  detected.  In  multivariate  logistic 
regression, baseline characteristics that remained in the 
final  model as  independent  predictors of  early  death 
were  DIC,  major  bleeding  and  higher  age  (Table 
5).
32,33,71
Response  to  treatment: As  mentioned  above,  all  80 
patients  that  completed  induction  therapy  and  were 
evaluated for response achieved CHR. Seven patients Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 4. Early death. Main characteristics of patients. 
Characteristic Distribution
N 14
Day of death, median (range) 6 (1-24) (Day1: 3, Day2: 3, Day4: 1, Day 8: 1, Day 10: 1, Day 12: 1, Day 14: 2, Day 19: 1, Day 24: 1)
Age, median (range) 52.5 (38-84)
Gender Male 8/14 (57.1%) Female 6/14 (42.9%),
WBC count /uL, median (range) 10795 (850-106600)
PLT count /uL, median (range) 13000 (5000-30000)
Sanz score Intermediate 7/14 (50%), High 7/14 (50%)
DIC 13/14 (92.9%)
Major hemorrhage 9/14 (64.3%)
Infection 6/12 (50%)
Intracranial bleeding 7/14 (50%)
Number of major bleeding sites 0: 5/14 (35.7%), 1: 6/14 (42.7%), 2: 3/14 (21.4%)
APL variant Hypergranular: 11/14 (78.6%), Microgranular: 3/14 (21.4%)
Secondary disease 1/14 (7.1%)
PML-RARα isoform bcr1: 4/12 (33.3%), bcr2: 1/12 (8.3%), bcr3: 7/12 (58.3%)
FLT3 wt: 1/8 (12.5%), ITD: 5/8 (62.5%), TKD: 2/8 (25%)
Κaryotype t(15;17): 3/5 (60%), t(15;17) del 9q: 1/5 (20%), 46XX add 16, 46XX: 1/5 (20%)
Immunophenotype CD56 negative 5/5, CD7 negative 9/9, CD2 negative 8/8
died before induction therapy was introduced and eight 
died early after induction. The cumulative incidence of 
CHR from the beginning of the induction therapy was 
85.1% (95% CI, 76.1-90.9).(Figure 1) At the end of 
the  consolidation  therapy  73  of  the  75  evaluable 
patients  achieved  molecular  remission.  Only  two 
patients never achieved molecular remission. Both died 
after aggressive chemotherapy or allogeneic stem cell 
transplantation.
83,90 With  a  median  follow-up  of  the 
surviving patients  of  55 months (range,  1.3-182) the 
OS at 5 years was 78.4% (95% CI, 68.5-85.5). The OS 
for the patients of the low/intermediate risk group was 
83.1% and that of the high risk group 62.9%. (Table 6, 
Figure 2) If we consider only the patients that received 
full induction therapy (i.e. until day 8, n=87), the OS at 
5 years was 84.7% (95% CI, 75.1-90.8).
Ten patients relapsed. In seven patients the relapse 
was molecular and in three hematologic. There was no 
case of extramedullary relapse. Most of these patients 
were treated with ATO.
91,92 Two patients died during 
salvage therapy. Six achieved molecular remission and 
Table 5. Univariate and multivariate logistic regression analysis of early death risk.
Univariate logistic regression
Variable OR p n
Age (per year increase) 1.053 0.012 94
WBC ≥10000 vs <10000 4.33 0.016 94
PLT <40000 vs ≥40000 0.01 (Pearson χ2)* 94
Sanz score high vs low/intermediate 4.33 0.016 94
DIC 12.37 0.018 94
Major hemorrhage 6.67 0.002 94
Infection at diagnosis 2.8 0.104 88
FLT3 ITD 9.72 0.008 49
* None of the pts presenting with PLT≥40000 experienced early death
ii. Multivariate logistic regression 94
Variable OR p
DIC 9.1 0.05
Major hemorrhage 5.31 0.024
Age (per year increase) 1.07 0.007
Variables  included  in  the  initial  model:  age  (continuous),  high  vs  low/intermediate  Sanz  score,  DIC major  hemorrhage,  infection  at 
diagnosis, FLT3 ITD positivity.Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Cumulative incidence of hematologic response (N=94).
proceeded to  autologous stem cell transplantation. In 
all  these  six  cases  the  graft  was  PML-RARα
negative.
91,93 Five of these six patients are alive and in
molecular  remission  for  2-124  months  after  the 
transplantation  (median,  36).  Three  relapsed  patients 
did not achieve molecular remission and proceeded to 
allogeneic stem cell transplantation. All had an HLA 
identical  sibling.  They  are  alive  and  in  molecular 
remission  62,  70,  and  118  months  after  the 
transplantation.  The  cumulative  incidence  of  relapse 
(calculated from the date of CHR) was 18.3% (95% CI, 
9.9-28.7). It was 14.8% for the low/intermediate risk 
group and 33.5% for the high risk group (univariate, 
HR=2.21, p=0.195). (Table 6, Figure 3) Two patients 
developed a myelodysplastic syndrome 4 months and 3 
years  after  the  diagnosis  of  APL.
36,37,44,51,94 Both  are 
alive and in complete molecular remission concerning 
PML/RARα seven  months  and  eight  years  since  the 
diagnosis of MDS, respectively. 
The DFS for all 80 patients that achieved CHR was 
73.6%.  The  DFS  of  the  patients  belonging  to  the 
low/intermediate risk group was 75.1%, and of those 
belonging  to  the  high  risk  group  66.5%.  (Table  6, 
Figure 4)
The results of univariate and multivariate analysis 
concerning overall survival are shown in tables 7 and 
8.  The  same  factors  were  studied  with  univariate 
analysis for the DFS and the CIR. None proved to be 
significant (data not shown). 
Discussion.  In  this  study  we  present  the  clinical, 
immunophenotypic,  cytogenetic,  and  molecular 
findings as well as the clinical course of 95 Greek APL 
patients from 6 hospitals in Greece and Cyprus. Since 
there is not a national registry for this particular type of 
AML in Greece, the present study represents the largest 
series ever reported. 
Demographics  do  not  seem  to  differ  substantially 
from  previous  literature  reports.
43,45,51
Immunophenotyping  is  a  useful  tool  for  the  correct 
diagnosis.  Intermediate  to  high  side  scatter,  strong 
CD33  expression  and  MPO  positivity,  CD34+/-, 
CD13++, CD15+ dim and lack of HLA-DR expression 
were characteristic findings in almost all cases studied. 
Table 6. OS, DFS and CIR estimates
Risk group OS at 5 y
(95% CI) P DFS at 5 y
(95% CI) P CIR at 5 y
(95% CI) P
All Patients 78.4%
(68.5-85.5)
73.6%
(61.0-82.7)
18.3%
(9.9-28.7)
Low/intermediate 83.1%
(72.1-90.0)
75.1%
(61.2-84.6)
14.8%
(6.8-25.7)
High 62.9%
(39.2-79.5) 0.06 66.5%
(32.7-86.2) 0.7 33.5%
(9.9-59.5) 0.195
Figure 2. Kaplan-Meier estimated Overall Survival curves. A: all patients (n=94). B: according to Sanz score.
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Figure 1. Relapse cumulative incidence. A: all patients (N=80). B: according to Sanz score.
Figure 2. Kaplan-Meier estimated Disease Free Survival curves. A: all patients (n=94). B: according to Sanz score.
The  only  patient  showing  HLA-DR  expression  was 
found to be PML-RARα negative since her cytogenetic
abnormality  was  t(11;17).
58-61 We  noticed  a  strong 
correlation  between  the  expression  of  lymphoid 
markers  and  the  development  of  differentiation 
syndrome since 7/8 cases expressing lymphoid markers 
developed  the  syndrome.  By  far  the  most  frequent 
lymphoid marker expressed was CD2, a cell adhesion 
molecule. An explanation for such a correlation might 
be the adherence of the cells expressing such molecules 
to  the  capillary  endothelium  with  consequent 
inflammation.
95 There were only two cases with CD56 
expression, a rather low incidence and, therefore, no 
conclusions about its significance can be drawn. 
96
Taking into account that cytogenetically cryptic PML-
RARα rearrangements are observed in 4%-6% of APL 
cases,  we  found a  rather high  number of  cases  with 
normal  cytogenetics,  9/68  (13.2%).  Chance  and 
‘technical reasons’  are  the only  explanations  we can 
offer  for  this  finding.
5,16,26 Additional  chromosomal 
abnormalities were found in 15/59 cases (28.8%) and 
trisomy 8 was by far the most frequent abnormality. 
These findings are in accordance to other reports. The 
presence of additional chromosomal abnormalities did 
not influence the response to treatment. We therefore 
agree with the suggestion that ACAs is not a reason to 
intensify treatment.
11-15 The prognostic significance of 
ider(17q) and three way translocations of t(15;17) are 
currently  unknown  due  to  their  low  incidence.
41 In 
addition, the third chromosome that is involved in the 
three way translocation to the t(15;17) varies. One of 
the two variant translocations involving chromosomes 
15, 17 and 18 was associated with a submicroscopic 
deletion of the 5’ part of the RARα gene, as evidenced 
by FISH.
97 Because only limited number of studies has 
examined  such  deletions  associated  with  the  PML-
RARa fusion  gene,  their  significance  and  their 
involvement in the pathogenesis of the disease if any, 
remain unclear. One of our patients manifested t(8;21) 
in  addition  to  the  t(15;17).  Although  the  patient 
received  induction  therapy  according  to  the  AIDA 
protocol  and  subsequently  two  cycles  of  high  dose 
cytarabine  with  idarubicin  and  ATRA  he  did  not 
achieve  molecular  remission.  The  co-existence  of 
t(15;17) and t(8;21) in a single leukemic clone is a very 
rare finding and the results of the few reported cases 
are  conflicting.  However,  it  has  been  proposed  that 
PML-RARa  and  AML1/ETO  fusion proteins  may
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Table  7.  Characteristics  and  postremission  outcome  of  APL 
patients (univariate analysis)
% OS
Characteristic No. of 
patients at 3 y at 5 y HR p
Overall 94 78.4% 78.4%
Gender
           Male 56 79.9% 79.9% 0.7 0.35
          Female 38 76.2% 76.2%
Age
          ≥60 25 84% 84% 2.92 0.015
          <60 69 61% 61%
WBC
          ≥10000 22 62.9% 62.9% 2.25 0.068
          <10000 72 83.1% 83.1%
PLT
          <40000 67 74.4% 74.4% 2.84 0.093
          ≥40000 27 88.3% 88.3%
Sanz score
          high 22 62.9% 62.9% 2.25 0.068
          
low/intermediate 72 83.1% 83.1%
DIC
          yes 54 68.1% 68.1% 2.72 0.006
          no 40 92.4% 92.4%
MH
          yes 26 57.2% 57.2% 3.46 0.004
          no 68 86.5% 86.5%
FLT3 ITD
          ITD 11 54.6% 54.6% 3.86 0.016
          wt/TKD 38 80.7% 80.7%
FLT3 TKD
          TKD 9 77.8% 77.8% 0.75 0.7
          wt/ITD 42 72.8% 72.8%
Infection at 
diagnosis
          yes 26 68.6% 68.6% 2 0.136
          no 62 83.8% 83.8%
FAB type
          microgranular 16 81.25% 81.25% 0.77 0.675
          hypergranular 76 77.2% 77.2%
PML-RARα Isoform
          bcr1 38 72.2% 72.2%
          bcr3 33 78.8% 78.8% 0.93 0.88
Karyotype group
          sole t(15;17) 37 83.1% 83.1%
          t(15;17) with 
ACAs 15 79% 79% 1.26 0.742
Secondary APL
          no 85 72.3% 72.3%
          yes 9 88.9% 88.9% 0.9 0.893
MH: major hemorrhage 
mutually  affect  their  pathogenetic  mechanism, 
rendering  the  cells  resistant  to  ATRA  which  is  in 
agreement with the resistance of our patient to ATRA 
based treatment.
38,80,81
In the  Greek origin patients the L isoform of the 
PML-RARa was  the  most  frequent  and  this  is  in 
agreement  with  previous  reports.  In  contrast,  in  the 
Cyprus  origin  patients  we  noticed  a  very  high 
frequency  of  the  S  isoform.
5,17,18 We  can  offer  no 
explanation  for  this  finding  and  it  definitely  needs 
confirmation. The  presence  of  FLT3 mutations  was 
associated with various adverse features and generally 
with  intermediate/high  risk  score,  as  previously 
reported.  It  seems  therefore  that  these  mutations  are 
inherently connected with the biology of the disease. 
We  observed  one  patient  showing  the  FLT3  TKD 
permanently  for  4  years  while  being  in  complete 
molecular  remission.  Such  a  finding  supports  the 
suggestion of not using FLT3 mutations as a marker for 
minimal residual disease in APL.
22,69,98,99
One  important  finding  of  our  study  was  the 
considerable  early  death  rate.  Actually  there  were 
14/94 early deaths (14.9%), with half of these patients 
dying  within  the  first  few  days  before  they  could 
receive full induction treatment. Hemorrhage was the 
main  cause  of  early  death.  (Table  4)
32,33,35,71Such  a 
figure is increased compared to the numbers reported 
in  the  clinical  trials  of  APL  (3%-10%).  However, 
population based studies have confirmed that the early 
death rate reported in clinical trials does not correspond 
to  real  life  circumstances  and  worryingly,  such  a 
finding has not appreciably changed in the ATRA era. 
Delays in referring the patients, delays in establishing 
diagnosis,  and  failure  to  promptly  begin  specific 
treatment  on  clinical  suspicion  and  to  provide 
aggressive  supportive  therapy  are  factors  explaining 
such mortality and are the targets of the interventions 
urgently needed. Moreover, our data suggest that much 
of the prognostic effect of significant variables on OS 
outcome  largely  stems  from  the  effect  of  these 
variables on the risk of early death. (Tables 5, 7, and 
8) This is also supported by the observation that these 
variables  had  no  discernible  effect  on  disease-free 
survival  or  relapse  incidence.  As  regards  patients 
surviving  induction  treatment  the  response  was 
excellent. All 80 evaluable patients achieved complete 
hematologic remission. At the end of the consolidation 
therapy  73/75  achieved  molecular  remission.  These 
results are in accordance to the relevant reports of the 
protocols  that  our  patients  followed (AIDA0493,  the 
LPA1999 and LPA2005 PETHEMA and the European 
APL1993  and  APL2000). 
30,35,43-51 Only  two  patients 
showed  primary  resistance,  i.e.  they  never  achieved 
molecular remission. Both died after being treated with 
aggressive  chemotherapy or  allogeneic stem  cellMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 8. Multivariate Cox regression analysis of Overall Survival
Overall Survival-Multivariate analysis: i. FLT3 ITD included 
(N=49)
Variable HR p
FLT3 ITD vs wt/TKD 3.48 0.029
Major hemorrhage 3.75 0.028
High vs low Sanz score 2.66 0.093
Overall  Survival-Multivariate  analysis:  ii.  FLT3  ITD  not 
included (N=94)
Variable HR p
Age (≥60 vs <60) 2.49 0.038
DIC 3.86 0.036
Major hemorrhage 2.22 0.073
Variables  included  in  the  initial  model:  age  (≥60  vs  <60),  Sanz 
score (high vs low and int vs low or high vs low/int), PLT (<40000 
vs ≥40000), DIC, major hemorrhage, infection at diagnosis, FLT3 
ITD vs other
transplantation. We observed 10 relapses (cumulative 
incidence  of  relapse  18.3%,  95%  CI  9.9%-28.7%) 
(Figure 3). Because  of  the  close  monitoring most 
relapses were molecular and therefore the patients were 
salvaged rather  early. The salvage treatment  (for the 
majority ATO and autologous or allogeneic stem cell 
transplantation) was successful: five patients remain in 
molecular  remission  for  2-124  months  (median,  36) 
after  autologous  stem  cell  transplantation  and  three 
patients for 62-118 months after allogeneic stem cell 
transplantation.  These  results  further  support  the 
importance of the close molecular monitoring after the 
first  line  treatment  is  completed.
65,100-102 No  CNS 
relapse was observed in the cohort of our patients in 
none of whom CNS prophylaxis was given.
27,52 There 
were  two  patients  that  developed  myelodysplastic 
syndrome,  an  incidence  not  different  from  the  one 
reported. 
27,36,37,40,44,51,94 We were unable to confirm the 
value of various well established risk factors for the 
patients’ outcome. Most probable explanations are the 
rather small numbers in our study as well as the risk 
adapted  therapy  that  was  provided  to  most  of  our 
patients. In summary, our data  confirm the  excellent 
results of the current treatment of the disease, provided 
that the patient will survive the early period after the 
disease has been diagnosed.
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